Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Priyanka SharmaQamar J Khan

Abstract

Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisite randomized phase II trial was to assess efficacy of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens. Patients aged ≥18 years with stage I-III TNBC were randomized (1:1) to receive either paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A), or carboplatin AUC6 + docetaxel (D) every 21 days × 6 (CbD, arm B). Stromal tumor-infiltrating lymphocytes (sTIL) were assessed. Primary endpoint was pCR in breast and axilla. Other endpoints included residual cancer burden (RCB), toxicity, cost, and event-free (EFS) and overall survival (OS). One hundred patients were randomized; arm A (n = 48) or arm B (n = 52). pCR was 54% [95% confidence interval (CI), 40%-69%] in arm A and 54% (95% CI, 40%-68%) in arm B. RCB 0+I rate was 67% in both arms. Median sTIL density was numerically higher in those with pCR compared with those with residual disease (20% vs. 5%; P = 0.25). At medi...Continue Reading

Associated Clinical Trials

References

Apr 28, 2000·BMJ : British Medical Journal·S G Thompson, J A Barber
Aug 2, 2005·Medical Care·Michael Drummond, Mark Sculpher
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Sep 6, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansLajos Pusztai
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertGunter von Minckwitz
Jan 16, 2010·Journal of Biopharmaceutical Statistics·Matthew S MayoSeng-Jaw Soong
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Banu ArunConstance Albarracin
Jun 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura J EssermanNola Hylton
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertSibylle Loibl
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffJudith E Karp
Mar 3, 2015·Annals of Surgical Oncology·Patricia Cortazar, Charles E Geyer
Jul 4, 2015·Comprehensive Physiology·Timothy C TanMarielle Scherrer-Crosbie
Jun 16, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Priyanka SharmaMiguel Martin
Apr 25, 2017·Journal of Oncology Practice·Eric TaiLisa C Richardson
Aug 1, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Priyanka SharmaMiguel Martín
Aug 3, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J BursteinUNKNOWN Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Oct 29, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Priyanka SharmaDaniel F Hayes
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J BursteinUNKNOWN Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Feb 27, 2020·The New England Journal of Medicine·Peter SchmidUNKNOWN KEYNOTE-522 Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.